Earnings Report: May 1, 2023

 Earnings Spotlight: May 1, 2023


    Today marks the first day of trading in March. I had two of my holdings report earnings this afternoon. I will break down the earnings and my thoughts. April saw the markets rise, so let's see what this month has in store. 

Arista Networks, Inc. ($ANET)- Arista Networks reported earnings after the market closed this afternoon. The stock is seeing a sharp decline in after-hours trading. The company works on client to cloud networking for large data centers, campus and routing environments. The results looked pretty impressive with top and bottom line numbers beating Wall Street estimates. The forward guidance also looked solid, and that also beat the expectations of Wall Street. I was honestly knocked off my socks to see how much growth the company has seen since Q1 last year. They are also dipping into AI and working on customer's AI strategies. I think one thing that is holding up the company is the macroeconomic uncertainty that is stumping every company. The CEO of Arista expresses this concern and is hinting at a gradually recovery to the supply chain. 

My Thoughts: Arista continues to impress, the decline in the stock price definitely looks like an opportunity to jump into this one. I probably won't add here due to the fact of all the uncertainty in the economy. I can't express how much the growth and innovation plays into the success of this company. It looks to be doing very solid right now and hopefully they can keep on this trend. I want to see how they come along with AI. I am looking for continuous growth in this one and the extent into which they are innovating. Love the quarter and love the results, I am satisfied. 


Vertex Pharmaceuticals Incorporated ($VRTX)- Vertex Pharmaceuticals reported earnings after the market closed this afternoon. The stock is currently declining in after-hour trading. Vertex is a biotechnology company that invests in innovation to create medicines for people with serious diseases. The company beat top and bottom line estimates that were formulated by Wall Street Experts. The guidance was bleak and was not what experts were looking for after a solid quarter. The company got its TRIKAFTA drug approved in the US for children aged 2 to 5. Revenue grew by 13% in comparison with the last quarter. Cystic Fibrosis seems to be a focus of the company and they are growing like crazy with the drugs they have produced to treat it. This upcoming FY looks to be promising as the company is going to be rolling out some new things and looking to have some success on the late stages of some of their clinical trials. 

My Thoughts: This quarter was nothing but impressive for the company as they continue to innovate with the types of drugs they have to offer. While being a leader in Cystic Fibrosis they are continuing to diversify among other diseases to try and develop another drug. I love the way some of the clinical trials are doing, and they are looking promising for a big year. Although the guidance was disappointing after a solid quarter, I think there is some upside with this company. They look to be heading down the right path and are growing at a decent rate. Keep an eye out for the approval of the drugs continuing. Solid quarter for the company. 



Thanks for Reading,


All information was found in the company's earnings releases.

Comments

Post a Comment

Popular posts from this blog

Weekly Earnings Review: September 25, 2023- September 29, 2023

     It was a nice little break in the earnings report, but just like that we are back! We are slowly easing our way back into earnings season. However, this week marked the end of Q3 and September. September was a downturn from the rally we saw earlier in the year. There is a lot of stuff looming as the government is set to shut down on October 1st. The Fed is keeping a close eye on inflation but this weeks prints showed some signs of improvement. The average consumer is struggling as savings keep dwindling. In terms of our earnings, we just had two companies that reported this week. One is a warehouse style retailer and the other is a wide range consulting firm.  Tuesday, September 26, 2023 Costco Wholesale Corporation (COST)-     Costco beat expectations on both the top and bottom line. The stock saw a decline after the initial earnings report, but by the end of the week it has hit a new 52-week high. The revenue growth was impressive as it grew by a hair under 10%. The COGS growth
Read more

Weekly Earnings Review: October 16, 2023- October 20, 2023

      Well earnings season is finally among us, so we will start producing more beefier blog posts and cover a lot more companies over these next few weeks. I had one company report last week that I decided to throw into this weeks post, because I felt that it was pointless to make a post with just one boring company. With the inclusion of that company, we will cover 7 companies that report earnings this week and will give your our thoughts and opinions on how they performed during the quarter and the outlook. There is a lot of controversy going on with a war breaking out in Israel and the House of Representatives with out a speaker. This year seems to be the year of how geopolitics affect the market. There seems to be a lot of confusion with the outlook of the market right now, but inflation numbers still look to be fair and the earnings of major companies will be able to tell us a little bit more about where this is headed.  Thursday, October 12, 2023 Walgreens Boots Alliance (WBA)-
Read more

Weekly Earnings Review: November 27, 2023- December 1, 2023

Image
     Stocks continue to rise as we enter the final month of trading for the year. The S&P 500 and Nasdaq had another stellar month. Bond yields continue to fall, as interest rates have seemed to reach their peak. Estimates are all over the place when it comes to when cutting will start and how many cuts we will see next year. I added a new mantra to particular companies. I want to add some visual pieces to the post to entice the readers. Hope you guys enjoy the visuals and the excerpts. Stay investing! Monday, November 27, 2023 Zscaler (ZS)-      Zscaler continues to carry its momentum, as the company beat on both the top and bottom lines. The company achieved 40% growth on the top line and saw impressive growth on the bottom line as well. Management raised guidance and are expecting around 30% growth on both the top and bottom line. What is so impressive about this company is that they are achieving high growth and high profitability. This is a feat that a lot of software companie
Read more